Diagnostic, Prognostic and Therapeutic Potential of Long Noncoding RNAs in Cancer

Overview

Journal Mol Biol Rep

Specialty Molecular Biology

Date 2022 Jan 24

PMID 35072835

Authors

Muhammad Babar Khawar

Syeda Eisha Hamid

Tayyba Jan

Muddasir Hassan Abbasi

Muhammad Idnan

Nadeem Sheikh

Affiliations

Soon will be listed here.

Abstract

Long noncoding RNAs (lncRNAs) are longer than 200 nucleotides in length and undergo splicing, capping, polyadenylation, and editing just like mRNA. Evidence is growing that they regulate transcription, splicing, RNA degradation, and translation of genes and that their expression has been linked to a variety of illnesses, including cancer. The advancement of next-generation and high-throughput sequencing has changed the way lncRNAs are identified and characterized, revealing a relationship between lncRNAs and several tumor types. Since then, they have gained a significant attraction as a promising candidate in cancer diagnosis, prognosis, and therapy. Furthermore, they are a good candidate for consideration as tumor biomarkers due to their high stability, better tissue/cell selectivity, aberrant expression in certain malignancies, and easy and noninvasive detection. In addition, lncRNAs are being examined as therapeutic targets in clinical trials for a variety of malignancies. This review highlights the potential of lncRNAs as biomarkers or therapeutic targets in light of the current progress, clinical investigations, and patents filed so far.

Citing Articles

Circadian genes and non-coding RNAs: interactions and implications in cancer.

Yoon G, Roh J, Jang W, Kim W Anim Cells Syst (Seoul). 2025; 29(1):135-148.

PMID: 39944901 PMC: 11816739. DOI: 10.1080/19768354.2025.2459622.

ST8SIA6-AS1, a novel lncRNA star in liver cancer.

Qiu C, Fan H, Tao S, Deng Z, Luo H, Liu F Front Cell Dev Biol. 2024; 12:1435664.

PMID: 39211393 PMC: 11358109. DOI: 10.3389/fcell.2024.1435664.

LINC00540 promotes sorafenib resistance and functions as a ceRNA for miR-4677-3p to regulate AKR1C2 in hepatocellular carcinoma.

Xu K, Wang X, Hu S, Tang J, Liu S, Chen H Heliyon. 2024; 10(5):e27322.

PMID: 38463802 PMC: 10920722. DOI: 10.1016/j.heliyon.2024.e27322.

Long noncoding RNA ABHD11-AS1 interacts with SART3 and regulates CD44 RNA alternative splicing to promote lung carcinogenesis.

Wang P, Liu Z, Sweef O, Xie J, Chen J, Zhu H Environ Int. 2024; 185:108494.

PMID: 38364571 PMC: 11375692. DOI: 10.1016/j.envint.2024.108494.

lncRNA-microRNA axis in cancer drug resistance: particular focus on signaling pathways.

Saleh R, Al-Ouqaili M, Ali E, Alhajlah S, Kareem A, Shakir M Med Oncol. 2024; 41(2):52.

PMID: 38195957 DOI: 10.1007/s12032-023-02263-8.

References

Huarte M . The emerging role of lncRNAs in cancer. Nat Med. 2015; 21(11):1253-61. DOI: 10.1038/nm.3981. View

Klingenberg M, Matsuda A, Diederichs S, Patel T . Non-coding RNA in hepatocellular carcinoma: Mechanisms, biomarkers and therapeutic targets. J Hepatol. 2017; 67(3):603-618. DOI: 10.1016/j.jhep.2017.04.009. View

de Oliveira J, Oliveira L, Mathias C, Pedroso G, Lemos D, Salviano-Silva A . Long non-coding RNAs in cancer: Another layer of complexity. J Gene Med. 2018; 21(1):e3065. DOI: 10.1002/jgm.3065. View

Iyer M, Niknafs Y, Malik R, Singhal U, Sahu A, Hosono Y . The landscape of long noncoding RNAs in the human transcriptome. Nat Genet. 2015; 47(3):199-208. PMC: 4417758. DOI: 10.1038/ng.3192. View

Guttman M, Amit I, Garber M, French C, Lin M, Feldser D . Chromatin signature reveals over a thousand highly conserved large non-coding RNAs in mammals. Nature. 2009; 458(7235):223-7. PMC: 2754849. DOI: 10.1038/nature07672. View

Vucicevic D, Corradin O, Ntini E, Scacheri P, Orom U . Long ncRNA expression associates with tissue-specific enhancers. Cell Cycle. 2015; 14(2):253-60. PMC: 4614992. DOI: 10.4161/15384101.2014.977641. View

Gutschner T, Diederichs S . The hallmarks of cancer: a long non-coding RNA point of view. RNA Biol. 2012; 9(6):703-19. PMC: 3495743. DOI: 10.4161/rna.20481. View

Flippot R, Malouf G, Su X, Mouawad R, Spano J, Khayat D . Cancer subtypes classification using long non-coding RNA. Oncotarget. 2016; 7(33):54082-54093. PMC: 5288243. DOI: 10.18632/oncotarget.10213. View

Yao R, Wang Y, Chen L . Cellular functions of long noncoding RNAs. Nat Cell Biol. 2019; 21(5):542-551. DOI: 10.1038/s41556-019-0311-8. View

10.

Yan X, Hu Z, Feng Y, Hu X, Yuan J, Zhao S . Comprehensive Genomic Characterization of Long Non-coding RNAs across Human Cancers. Cancer Cell. 2015; 28(4):529-540. PMC: 4777353. DOI: 10.1016/j.ccell.2015.09.006. View

11.

Arita T, Ichikawa D, Konishi H, Komatsu S, Shiozaki A, Shoda K . Circulating long non-coding RNAs in plasma of patients with gastric cancer. Anticancer Res. 2013; 33(8):3185-93. View

12.

Redova M, Sana J, Slaby O . Circulating miRNAs as new blood-based biomarkers for solid cancers. Future Oncol. 2013; 9(3):387-402. DOI: 10.2217/fon.12.192. View

13.

Groskopf J, Aubin S, Deras I, Blase A, Bodrug S, Clark C . APTIMA PCA3 molecular urine test: development of a method to aid in the diagnosis of prostate cancer. Clin Chem. 2006; 52(6):1089-95. DOI: 10.1373/clinchem.2005.063289. View

14.

Hessels D, Klein Gunnewiek J, van Oort I, Karthaus H, van Leenders G, van Balken B . DD3(PCA3)-based molecular urine analysis for the diagnosis of prostate cancer. Eur Urol. 2003; 44(1):8-15; discussion 15-6. DOI: 10.1016/s0302-2838(03)00201-x. View

15.

Wang F, Ren S, Chen R, Lu J, Shi X, Zhu Y . Development and prospective multicenter evaluation of the long noncoding RNA MALAT-1 as a diagnostic urinary biomarker for prostate cancer. Oncotarget. 2014; 5(22):11091-102. PMC: 4294360. DOI: 10.18632/oncotarget.2691. View

16.

Zhang K, Luo Z, Zhang Y, Zhang L, Wu L, Liu L . Circulating lncRNA H19 in plasma as a novel biomarker for breast cancer. Cancer Biomark. 2016; 17(2):187-94. DOI: 10.3233/CBM-160630. View

17.

Vennin C, Spruyt N, Dahmani F, Julien S, Bertucci F, Finetti P . H19 non coding RNA-derived miR-675 enhances tumorigenesis and metastasis of breast cancer cells by downregulating c-Cbl and Cbl-b. Oncotarget. 2015; 6(30):29209-23. PMC: 4745721. DOI: 10.18632/oncotarget.4976. View

18.

Zhan H, Tu S, Zhang F, Shao A, Lin J . MicroRNAs and Long Non-coding RNAs in c-Met-Regulated Cancers. Front Cell Dev Biol. 2020; 8:145. PMC: 7078111. DOI: 10.3389/fcell.2020.00145. View

19.

Verhaegh G, Verkleij L, Vermeulen S, den Heijer M, Witjes J, Kiemeney L . Polymorphisms in the H19 gene and the risk of bladder cancer. Eur Urol. 2008; 54(5):1118-26. DOI: 10.1016/j.eururo.2008.01.060. View

20.

Yanez-Mo M, Siljander P, Andreu Z, Bedina Zavec A, Borras F, Buzas E . Biological properties of extracellular vesicles and their physiological functions. J Extracell Vesicles. 2015; 4:27066. PMC: 4433489. DOI: 10.3402/jev.v4.27066. View